Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-12-25
2007-12-25
O'Sullivan, Peter (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S210200, C514S253010, C514S318000, C514S332000, C514S336000, C514S341000, C514S343000, C544S360000, C546S194000, C546S256000, C546S309000
Reexamination Certificate
active
10115135
ABSTRACT:
Novel benzamide compounds, their salts and compositions related thereto having activity against mammalian Factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders.
REFERENCES:
patent: 4588587 (1986-05-01), Gasic
patent: 6376515 (2002-04-01), Zhu et al.
patent: 6720317 (2004-04-01), Zhu et al.
patent: 6835739 (2004-12-01), Zhu et al.
patent: 6844367 (2005-01-01), Zhu et al.
patent: 2 301 559 (1999-03-01), None
patent: 798295 (1997-10-01), None
patent: WO 94/13693 (1994-06-01), None
patent: WO 97/21437 (1997-06-01), None
patent: WO 97/30971 (1997-08-01), None
patent: WO 98/28269 (1998-07-01), None
patent: WO 99/00121 (1999-01-01), None
patent: WO 99/00127 (1999-01-01), None
patent: WO 99/42439 (1999-08-01), None
patent: WO 01/19788 (2001-03-01), None
patent: WO 01/19788 (2001-03-01), None
patent: WO 02/079145 (2002-10-01), None
Herron et al., 2000, “1,2-dibenzamidobenzene inhibitors of human factor Xa,”J. Med. Chem. 43:859-872.
Wiley et al., 2000, “Structure-based design of potent, amidine-derived inhibitors of factor Xa: Evaluation of selectivity, anticoagulant activity, and antithrombotic activity,”J. Med. Chem. 43:883-899.
Claeson, G., “Synthetic Peptides and Peptidomimetics as Substrates and Inhibitors of Thrombin and Other Proteases in the Blood Coagulation System”,Blood Coag. Fibrinol., 1994. 5:411-436 (1994).
Elodi et al., “Optimization of conditions for the catalytic effect of the factor IXa-factor VIII complex: probable role of the complex in the amplification of blood coagulation”, Thromb. Res. 1979. 15:617-629.
Hauptmann, J. et al., “Comparison of the Anticoagulant and Antithrombotic Effects of Synthetic Thrombin and Factor Xa Inhibitors”, Thromb. Haemost., 1990. 63:220-223.
Hitomi, Y. et al., “Inhibitory Effect of New Synthetic Protease Inhibitor (FUT-175) on the Coagulation System”,Haemostasis, 1985. 15:164-168.
Kam, C.M. et al., “Mechanism Based Isocoumarin Inhibitors for Trypsin and Blood Coagulation Serine Proteases: New Anticoagulants”, Biochemistry, 1988. 27:2547-2557.
Nutt, E. et al., “The Amino Acid Sequence of Antistasin, a Potent Inhibitor of Factor Xa Reveals a Repeated Internal Structure”, J. Biol. Chem., 1988. 263:10162-10167.
Sturzebecher, J. et al., “Synthetic Inhibitors of Bovine Factor Xa and Thrombin. Comparison of Their Anticoagulant Efficiency”, Thromb. Res., 54:245-252 (1989).
Tidwell, R.R. et al., “Strategies for Anticoagulation With Synthetic Protease Inhibitors. Xa Inhibitors Versus Thrombin Inhibitors”, Thromb. Res., 1980. 19:339-349.
Turner, A.D. et al., “p-Amidino Esters as Irreversible Inhibitors of Factor IXa and Xa and Thrombin”, Biochemistry, 1986. 25:4929-4935.
Waxman, L., et al., “Tick Anticoagulant Peptide (TAP) is a Novel Inhibitor of Blood Coagulation Factor Xa”, Science, 248:593-596 (1990).
Bauer Shawn
Goldman Erick A.
Huang Wenrong
Jia Zhaozhong Jon
Scarborough Robert M.
Foley & Lardner LLP
Millennium Pharmaceuticals Inc.
O'Sullivan Peter
LandOfFree
Benzamide inhibitors of factor Xa does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzamide inhibitors of factor Xa, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzamide inhibitors of factor Xa will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3878365